Hims & Hers Health Shares Surge Nearly 14% in Pre-Market Trading Following Launch of Generic Wegovy Alternative
Stock News
Feb 05
On Thursday, shares of Hims & Hers Health Inc. (HIMS) surged nearly 14% in pre-market trading, reaching $27.77. The catalyst for the move was the company's announcement that it has begun offering a generic version of the newly launched weight-loss drug Wegovy at a promotional price of $49 per month, which is approximately $100 cheaper than the branded medication. Hims stated that the treatment can be customized for patients who wish to avoid side effects or prefer a pill form over an injection. "We are excited to find ways to continue launching branded treatment options across specialties through our platform. Having more choices available on the platform is the best outcome for our customers," said Andrew Dudum, CEO of Hims, in a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.